Antibodies News and Research

RSS

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.

25 Jan 2022

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

A new preprint available on medRxiv* demonstrates the marked improvement in the immune response when the mRNA vaccine BNT162b2, from Pfizer/BioNTech, is used for the third dose after a primary two-dose series of an inactivated whole virus vaccine.

25 Jan 2022

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

A new study investigated SARS-CoV-2 spike protein responses targeted by cross-reactive T cells that were isolated from convalescent COVID-19 individuals along with previously uninfected donors.

25 Jan 2022

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

A recent study evaluated the sensitivity and specificity of a “spit and mail” serology test.

25 Jan 2022

LA County study finds COVID-19 'herd immunity' unlikely

In a research letter published in the Journal of the American Medical Association (JAMA), researchers carried out a seroprevalence and vaccination coverage study in Los Angeles County (LAC).

24 Jan 2022

Neurological complications of the SARS-CoV-2 vaccine

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case series presenting with neurological manifestations after the coronavirus disease 2019 (COVID-19) vaccination, followed by a literature review, to propose hypotheses on how neurological symptoms might develop after vaccination.

24 Jan 2022

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

24 Jan 2022

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

In a study published in the latest issue of the Scientific Reports, a team of researchers constructed virus-like particles (VLPs) composed of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M), envelope (E), and nucleocapsid (N) proteins in tobacco plant using Agrobacterium-mediated delivery.

24 Jan 2022

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.

24 Jan 2022

Blood proteins could be potential targets for future drugs to slow aging process

Two blood proteins have been shown by scientists to influence how long and healthy a life we live, research suggests.

24 Jan 2022

Short- and long-term systemic responses in the golden hamster following SARS-CoV-2 or influenza A virus infection

A group of researchers used the golden hamster as a model system to better understand the long-term impacts of SARS-CoV-2 infection.

24 Jan 2022

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

A new study assessed the dynamics of IgG titers over 18 months in patients who had recovered from COVID-19 infections during March 2020.

24 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection

Scientists focused on determining the prevalence of OD eighteen months after COVID-19 infection.

24 Jan 2022

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

A new study measured T cell activity in vaccinated individuals and found a third vaccine provided substantial T-cell immunity against the Omicron variant of SARS-CoV-2.

24 Jan 2022

Research shows depletion of extracellular vesicles weakens immune response towards SARS-CoV-2

Over the past several years, considerable effort has been made towards developing better diagnostic and prognostic tools. However, until now, the focus of research has mainly been on the virus itself or the immune response it triggers. To unify diagnostic and prognostic tools for COVID-19 analyses, researchers propose using extracellular vesicles (EVs) from serum liquid biopsies.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

Antibodies News and Research

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Sensitivity and specificity of a “spit and mail” SARS-CoV-2 serology test

LA County study finds COVID-19 'herd immunity' unlikely

Neurological complications of the SARS-CoV-2 vaccine

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

Peptide-enhanced antibody therapy may help treat breast cancer metastasis to bone

Blood proteins could be potential targets for future drugs to slow aging process

Short- and long-term systemic responses in the golden hamster following SARS-CoV-2 or influenza A virus infection

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Prevalence of olfactory dysfunction 18 months after SARS-CoV-2 infection

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

Research shows depletion of extracellular vesicles weakens immune response towards SARS-CoV-2

Researchers are in the race to beat Omicron

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

From IHC to multiplexing: A practical guide for modern tissue analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo